Patient experience: Living with desmoid fibromatosis
December 4, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing desmoid fibrosis, feature, patient experience, pharma, rare disease
Lisa Pascoe lives with a rare, benign desmoid tumour in her abdomen. She opens up to Pharmafocus on her diagnosis …
Trump’s new FDA nominee advances in the Senate
December 4, 2019Research and Development Big Pharma, FDA, FDA commissioner, Trump, US Pharma
Dr Stephen Hahn, President Donald Trump’s FDA nominee, has advanced his nomination to the full Senate chamber. The vote was …
Male birth control drug may hold promise for treating lung cancer, Chinese study finds
December 4, 2019Research and Development Cancer Immunotherapy, Chinese Pharmaceuticals, Male Birth Control, lung cancer
A drug for male birth control may hold promise for treating lung cancer patients when treatments like immunotherapy do not …
FDA approves Johnson & Johnson cataract treatment
December 4, 2019Research and Development
Johnson & Johnson has secured approval from the FDA for its Tecnis Toris II 1-Piece Intraocular Lens (IOL). &nbs
Roche’s Tecentriq combo scores FDA approval in non-small cell lung cancer
December 4, 2019Research and Development, Sales and Marketing FDA, NSCLC, Roche, pharma, tecentriq
Roche’s immunotherapy Tecentriq (atelizumab) has chalked up another approval from the FDA, this time in combination with the chemotherapy Abraxane …
Purdue Pharma’s Richard Sackler ignored OxyContin addiction concerns, new emails show
December 3, 2019Manufacturing and Production, Sales and Marketing Opiod, Purdue Pharma, Richard Sackler, opiod crisis
A recently exposed 1997 email chain shows Dr Richard Sackler, member of the billionaire founding family of Purdue Pharma, knew …
AstraZeneca sells US/Canada rights for Seroquel for $41 million to “focus on main therapy areas”
December 3, 2019Manufacturing and Production, Sales and Marketing AstraZeneca, pharma
AstraZeneca has announced its intention to jettison the rights to two non-core drugs in the US and Canada in order …
Jeremy Corbyn writes Trump letter asking for reassurance over NHS in trade deal
December 3, 2019Manufacturing and Production Boris, Boris Johnson, Boris NHS, Jeremy Corbyn, Labour Party, NHS, Trump
Labour Party leader Jeremy Corbyn has written to US President Donald Trump demanding he confirm that he will not put …
Reagan-era FDA Commissioner Frank Young dies
December 3, 2019Manufacturing and Production FDA, FDA commissioner, Frank Young
Frank Young, FDA Commissioner from 1984-1989, died on 24 November. He was 88; his son, Jonathan, said the cause was …
Astellas poised to acquire neuromuscular disease specialist Audentes for $3bn all-cash
December 3, 2019Manufacturing and Production, Sales and Marketing Astellas, Audentes, acquisition, neuromuscular disease, pharma
Astellas Pharma is set to acquire US-based Audentes Therapeutics in an all-cash deal valued at $3 billion in cash, it …
Dr Richard Torbett is named as the new Chief Executive of the ABPI
December 2, 2019Sales and Marketing British pharmaceuticals, Dr Richard Corbett, apbi, appointments
The Association of the British Pharmaceutical Industry (ABPI) has appointed Dr Richard Torbett as its new Chief Executive. He will …
Exclusive interview: Samsung Bioepis’ Sang-Jin Pak on the rise of biosimilars
December 2, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Samsung Bioepis, biosimilars, pharma
Following on from our focus on biosimilars in our feature last week, you can read Nikhil Patel’s interview with Sang-Jin …
FDA urged to investigate use of unapproved drug on prisoners
December 2, 2019Sales and Marketing FDA, Opiods, US Opiods, opiod crisis
The Louisiana Department of Public Safety and Corrections (LDPSC) and BioCorRx Inc are alleged to have collaborated in testing an …
NICE authorises Lynparza for NHS use in all BRCA-mutated ovarian cancer cases
December 2, 2019Sales and Marketing Cancer, NHS, NICE, lynparza, ovarian cancer, pharma
NICE has given its recommendation for the routine use on the NHS in England and Wales of AstraZeneca and MSD’s …
Labour and Lib Dems make election pledge for wider access to HIV drug
December 2, 2019Sales and Marketing AIDS, Conservatives, HIV. HIV Drugs, Labour Party, Liberal Democrats, lib dems
The Labour Party and the Liberal Democrats have both pledged to roll out access to pre-exposure prophylaxis (PrEP) therapy for …
British pharmaceutical industry is threatened by Labour, says former Party health minister
December 2, 2019Sales and Marketing British pharmaceuticals, Election 2019, Jeremy Corbyn, Labour Party, NHS
A former Labour Party health minister has said that the British pharmaceutical industry is “under threat” from a Jeremy Corbyn …
Roche’s satralizumab shows promise at Phase 3 in neuromyelitis optica spectrum disorder
December 2, 2019Research and Development, Sales and Marketing Roche, pharma, satralizumab
Roche has presented new data on its interleukin-6 (IL-6) inhibitor satralizumab in the treatment of neuromyelitis optica spectrum disorder (NMOSD), …
Top Ten most popular articles on Pharmafile.com this week
November 29, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boris Johnson, Jeremy Corbyn, NHS, Opiod, US, opiod crisis
The NHS was featured heavily in the news this week. Jeremy Corbyn revealed documents detailing previous UK-US discussions in which …
Few in NHS trust tech firms handling patient data
November 29, 2019Medical Communications AI, Boris, Corbyn, NHS, NHS Brexit, johnson
Few in the NHS trust ‘big tech’ companies to handle patient data in a confidential manner, a recent YouGov poll …
Immupharma and Avion sign agreement for lupus drug Lupuzor
November 29, 2019Medical Communications Diseases, Lupus, Lupuzor, avion
Immupharma has signed a development agreement with Avion Pharmaceuticals to acquire the licensing rights for Lupuzor, a peptide therapeutic and …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
